Down Field Spectroscopy at Ultrahigh Fields

TRD3：超高场下场光谱学 项目绩效评估：Walter Witschey博士和Ravinder Reddy博士。 摘要 该技术研发部分专注于开发下场1H磁体 共振光谱(DFS)技术用于测量几种重要的代谢物(NAD+、谷氨酰胺、聚合酶链式反应、 肌氨酸和三磷酸腺苷)，它们不能从传统的高场光谱(UFS)中获得，并且用作 不同疾病的生物标志物。具体地说，它开发了新的技术，包括(I)光谱选择 具有最佳激发轮廓的激发脉冲和空间局域脉冲序列 无水抑制的短回声采集(II)检测和指定DFS代谢物的策略和 测量交叉松弛(III)能够同时提供UFS和 具有短回波捕获的DFS和(Iv)集成了接收线圈选择、涡流 校正和光谱曲线拟合及代谢物定量。这些技术发展是由 通过宾夕法尼亚大学内部和分布在美国各地的其他机构的协作和服务项目 以及在国外。成功完成这些目标将带来有助于改善我们的 了解骨骼肌和心脏的衰老、神经退行性变和线粒体疾病，从而 改进对这些疾病的诊断，并指导靶向治疗的发展和使 对这些疗法的疗效进行纵向评估。此外，这些技术的广泛传播， 潜在的商业化和对下一代生物医学科学家的培训将持续下去 对全国的影响。

TR&D3: Downfield Spectroscopy at Ultrahigh Fields Project PIs: Walter Witschey, Ph.D. and Ravinder Reddy, Ph.D. Abstract This technology research and development component focuses on the development of downfield 1H magnetic resonance spectroscopic (DFS) technologies to measure several important metabolites (NAD+, Glutamine, PCr, Carnosine and ATP) that are not accessible from the conventional upfield spectroscopy (UFS), and serve as biomarkers for different diseases. Specifically, it develops novel technologies including (i) Spectral selective excitation pulses and spatially localized pulse sequences with optimal excitation profiles and capable of ultra- short echo acquisition without water suppression (ii) Strategies to detect and assign the DFS metabolites and measure cross-relaxation (iii) Optimal metabolic cycling schemes capable of providing simultaneous UFS and DFS with short echo acquisition and (iv) a post-processing pipeline integrating receive coil selection, eddy current correction and spectral curve fitting and metabolite quantitation. These technological developments are driven by collaborations and service projects from within PENN and from other institutions distributed across the US and abroad. Successful completion of the goals will lead to technologies that contribute to our improved understanding of aging, neurodegeneration, mitochondrial disease in skeletal muscle and heart and, thereby improving diagnosis of these disorders and guiding the development of targeted therapies and enabling longitudinal evaluation of the efficacy of these therapies. Furthermore, wide dissemination of these technologies, potential commercialization, and training of the next generation of biomedical scientists, will have sustained national impact.